Recursion Pharmaceuticals
RXRX
RXRX
133 hedge funds and large institutions have $861M invested in Recursion Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 45 increasing their positions, 33 reducing their positions, and 21 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding in top 10
Funds holding in top 10: →
more capital invested
Capital invested by funds: $ → $
6.23% more ownership
Funds ownership: 58.75% → 64.98% (+6.2%)
4% more funds holding
Funds holding: 128 → 133 (+5)
15% less call options, than puts
Call options by funds: $499K | Put options by funds: $588K
Holders
133
Holding in Top 10
8
Calls
$499K
Puts
$588K
Top Buyers
| 1 | +$57.5M | |
| 2 | +$23.3M | |
| 3 | +$12.5M | |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$5.62M |
| 5 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
+$3.25M |
Top Sellers
| 1 | -$4.91M | |
| 2 | -$4.4M | |
| 3 | -$3.92M | |
| 4 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$3.06M |
| 5 |
Voloridge Investment Management
Jupiter,
Florida
|
-$2.22M |